INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47001, 'Interferon alfa-2a, Recombinant', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47071/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47002, 'Interferon alfa-2b', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47072/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47003, 'Interferon alfa-n1', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47073/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47004, 'Interferon alfacon-1', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47074/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47005, 'Interferon beta-1a', 'Brentuximab vedotin', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47075/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47006, 'Interferon beta-1b', 'Brentuximab vedotin', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47076/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47007, 'Interferon gamma-1b', 'Brentuximab vedotin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47077/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47008, 'Diiodohydroxyquinoline', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47078/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47009, 'Ipilimumab', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47079/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47010, 'Isavuconazonium', 'Brentuximab vedotin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47080/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47011, 'Isoniazid', 'Brentuximab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47081/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47012, 'Istradefylline', 'Brentuximab vedotin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47082/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47013, 'Itraconazole', 'Brentuximab vedotin', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47083/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47014, 'Ivacaftor', 'Brentuximab vedotin', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47084/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47015, 'Brentuximab vedotin', 'Ixabepilone', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47085/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47016, 'Brentuximab vedotin', 'Ixazomib', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47086/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47017, 'Brentuximab vedotin', 'Kava', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47087/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47018, 'Brentuximab vedotin', 'Ketoconazole', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47088/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47019, 'Brentuximab vedotin', 'Ketoprofen', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47089/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47020, 'Brentuximab vedotin', 'Labetalol', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Acebutolol, Nadolol, Propranolol, Metoprolol, Nebivolol, Bisoprolol, Sotalol, Timolol, Atenolol, Pindolol, Penbutolol, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47090/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47021, 'Brentuximab vedotin', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47091/', '[1] Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. "Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG." Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL "Lactobacillus bacteremia and endocarditis: review of 45 cases." Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML "Probiotic use in clinical practice: what are the risks?" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al "Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin." Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG." Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al "Lactobacilli and bacteremia in southern Finland, 1989-1992" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM "Lactobacillus endocarditis caused by a probiotic organism." Clin Microbiol Infect 5 (1999): 290-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47022, 'Brentuximab vedotin', 'Lapatinib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47092/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47023, 'Brentuximab vedotin', 'Larotrectinib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47093/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47024, 'Brentuximab vedotin', 'Lasmiditan', 'Moderate', 'Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.', NULL, 'Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.', NULL, 'Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.', 'Distribution', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47094/', '[1] "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47025, 'Brentuximab vedotin', 'Lefamulin', 'Moderate', 'When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.', NULL, 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', NULL, 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.', 'Metabolism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47095/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47026, 'Brentuximab vedotin', 'Leflunomide', 'Major', 'The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', NULL, 'Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa.', NULL, 'Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide''s active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47096/', '[1] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47027, 'Brentuximab vedotin', 'Lenalidomide', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Amivantamab, Ramucirumab, Rituximab, Sacituzumab govitecan, Trastuzumab deruxtecan, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47097/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47028, 'Brentuximab vedotin', 'Lenvatinib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47098/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47029, 'Brentuximab vedotin', 'Levodopa', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47099/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47030, 'Brentuximab vedotin', 'Levofloxacin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Enoxacin, Gatifloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Ciprofloxacin, Lomefloxacin, Grepafloxacin, Cinoxacin, Delafloxacin, Sparfloxacin, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47100/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47031, 'Brentuximab vedotin', 'Linagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47101/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47032, 'Brentuximab vedotin', 'Linezolid', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47102/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47033, 'Brentuximab vedotin', 'Liraglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47103/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47034, 'Brentuximab vedotin', 'Lisinopril', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47104/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47035, 'Brentuximab vedotin', 'Lixisenatide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47105/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47036, 'Brentuximab vedotin', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.', NULL, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, Alirocumab', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47106/', '[1] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47037, 'Brentuximab vedotin', 'Lomustine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Thiotepa, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Mechlorethamine, Bendamustine, Melphalan, Ifosfamide, Melphalan flufenamide, Uracil mustard', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47107/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47038, 'Brentuximab vedotin', 'Lonafarnib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Metabolism', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47108/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47039, 'Brentuximab vedotin', 'Lorlatinib', 'Moderate', 'Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is increased clearance due to lorlatinib-mediated induction of CYP450 3A4 metabolism.', NULL, 'Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4.', NULL, 'Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy. Avoid concomitant use with lorlatinib where minimal decreases in concentration of the CYP450 3A4 substrate may lead to serious therapeutic failure. If coadministration is required, the CYP450 3A4 substrate dosage should be increased in accordance with approved product labeling.', 'Metabolism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47109/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47040, 'Brentuximab vedotin', 'Lovastatin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47110/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47041, 'Brentuximab vedotin', 'Lurbinectedin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47111/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47042, 'Brentuximab vedotin', 'Lutetium Lu 177 dotatate', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47112/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47043, 'Brentuximab vedotin', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47113/', '[1] "Product Information. Lymerix (Lyme disease vaccine)." SmithKline Beecham, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47044, 'Brentuximab vedotin', 'Macitentan', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Riociguat, Metyrosine, Tadalafil', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47114/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47045, 'Brentuximab vedotin', 'Maraviroc', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47115/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47046, 'Brentuximab vedotin', 'Measles virus vaccine live attenuated', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47116/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47047, 'Brentuximab vedotin', 'Meclofenamic acid', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47117/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47048, 'Brentuximab vedotin', 'Mefenamic acid', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47118/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47049, 'Brentuximab vedotin', 'Meloxicam', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47119/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47050, 'Brentuximab vedotin', 'Meningococcal polysaccharide vaccine group C', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47120/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47051, 'Brentuximab vedotin', 'Mephenytoin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47121/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47052, 'Brentuximab vedotin', 'Mercaptopurine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Fluorouracil, Pemetrexed, Trifluridine, Floxuridine, Decitabine, Azacitidine, Capecitabine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47122/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47053, 'Brentuximab vedotin', 'Metaxalone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47123/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47054, 'Brentuximab vedotin', 'Methimazole', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Potassium perchlorate', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47124/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47055, 'Brentuximab vedotin', 'Methotrexate', 'Moderate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.', NULL, 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47125/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.[3] Nesher G, Mates M, Zevin S "Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis." Arthritis Rheum 48 (2003): 571-572', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47056, 'Brentuximab vedotin', 'Methyldopa', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Guanfacine, Rauwolfia serpentina root, Reserpine, Clonidine, Deserpidine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47126/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47057, 'Brentuximab vedotin', 'Methyltestosterone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Estradiol', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47127/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47058, 'Brentuximab vedotin', 'Metronidazole', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47128/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47059, 'Brentuximab vedotin', 'Midostaurin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47129/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47060, 'Brentuximab vedotin', 'Mifepristone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Ospemifene, Raloxifene, Bazedoxifene', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47130/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47061, 'Brentuximab vedotin', 'Miglitol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47131/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47062, 'Brentuximab vedotin', 'Milnacipran', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47132/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47063, 'Brentuximab vedotin', 'Minocycline', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Clindamycin, Vitamin A, Dexamethasone, Fluorometholone, Methylprednisolone, Azelaic acid, Adapalene, Tetracycline, Oxytetracycline, Doxycycline, Omadacycline, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47133/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47064, 'Brentuximab vedotin', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, Alirocumab', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47134/', '[1] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47065, 'Brentuximab vedotin', 'Moexipril', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47135/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47066, 'Brentuximab vedotin', 'Monomethyl fumarate', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47136/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47067, 'Brentuximab vedotin', 'Moxifloxacin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, Polymyxin B, Famciclovir, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47137/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47068, 'Brentuximab vedotin', 'Mumps virus strain B level jeryl lynn live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47138/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47069, 'Brentuximab vedotin', 'Nabumetone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47139/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47070, 'Brentuximab vedotin', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', 'Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47140/', '[1] "Product Information. ReVia (naltrexone)." DuPont Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47071, 'Brentuximab vedotin', 'Naproxen', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Ritodrine, Bremelanotide, Bromocriptine, Cabergoline, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47141/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47072, 'Brentuximab vedotin', 'Natalizumab', 'Major', 'Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.', NULL, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.', NULL, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47142/', '[1] "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47073, 'Brentuximab vedotin', 'Nateglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47143/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47074, 'Brentuximab vedotin', 'Naxitamab', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47144/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47075, 'Brentuximab vedotin', 'Nefazodone', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47145/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47076, 'Brentuximab vedotin', 'Nelarabine', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Fluorouracil, Pemetrexed, Trifluridine, Floxuridine, Decitabine, Azacitidine, Capecitabine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47146/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47077, 'Brentuximab vedotin', 'Nelfinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Metabolism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47147/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47078, 'Brentuximab vedotin', 'Neratinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47148/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47079, 'Brentuximab vedotin', 'Nevirapine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47149/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47080, 'Brentuximab vedotin', 'Niacin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47150/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47081, 'Brentuximab vedotin', 'Nicotinamide', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pyridoxine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47151/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47082, 'Brentuximab vedotin', 'Nilotinib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47152/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47083, 'Brentuximab vedotin', 'Nilutamide', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Relugolix, Degarelix, Aminoglutethimide, Exemestane', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47153/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47084, 'Brentuximab vedotin', 'Nintedanib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47154/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47085, 'Brentuximab vedotin', 'Niraparib', 'Moderate', 'Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.', NULL, 'Caution is advised if niraparib is prescribed with other myelosuppressive agents.', NULL, 'Caution is advised if niraparib is prescribed with other myelosuppressive agents.', 'Synergism', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47155/', '[1] "Product Information. Zejula (niraparib)." Tesaro Inc., Waltham, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47086, 'Brentuximab vedotin', 'Nitrofurantoin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47156/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47087, 'Brentuximab vedotin', 'Ocrelizumab', 'Moderate', 'The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.', NULL, 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.', NULL, 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47157/', '[1] "Product Information. Ocrevus (ocrelizumab)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47088, 'Brentuximab vedotin', 'Olaparib', 'Moderate', 'Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.', NULL, 'Caution is advised if olaparib is prescribed with other myelosuppressive agents.', NULL, 'Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47158/', '[1] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47089, 'Brentuximab vedotin', 'Omacetaxine mepesuccinate', 'Moderate', 'The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', NULL, 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.', 'Synergism', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Pertuzumab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Nivolumab, Pembrolizumab, Cemiplimab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47159/', '[1] "Product Information. Synribo (omacetaxine)." Teva Pharmaceuticals USA, North Wales, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47090, 'Brentuximab vedotin', 'Onasemnogene abeparvovec', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Risdiplam, Collagenase clostridium histolyticum, Hyaluronic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47160/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47091, 'Brentuximab vedotin', 'Orlistat', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Dexfenfluramine, Ephedrine, Fenfluramine, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47161/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47092, 'Brentuximab vedotin', 'Oxaliplatin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Pertuzumab, Avelumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, Pembrolizumab, Rituximab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47162/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47093, 'Brentuximab vedotin', 'Oxandrolone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47163/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47094, 'Brentuximab vedotin', 'Oxaprozin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47164/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47095, 'Brentuximab vedotin', 'Oxymetholone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47165/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47096, 'Brentuximab vedotin', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', NULL, 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', NULL, 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47166/', '[1] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47097, 'Brentuximab vedotin', 'Paclitaxel (protein-bound)', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47167/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47098, 'Brentuximab vedotin', 'Palifermin', 'Moderate', 'INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.', NULL, 'Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.', NULL, 'Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.', 'Others', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, Sacituzumab govitecan, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47168/', '[1] "Product Information. Kepivance (palifermin)." Shire US Inc, Florence, KY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47099, 'Brentuximab vedotin', 'Panobinostat', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47169/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47100, 'Brentuximab vedotin', 'Pasireotide', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Norethisterone, Nafarelin, Octreotide, Cetrorelix, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47170/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47101, 'Brentuximab vedotin', 'Pazopanib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47171/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47102, 'Brentuximab vedotin', 'Pegaspargase', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47172/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47103, 'Brentuximab vedotin', 'Pegfilgrastim', 'Moderate', 'INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.', NULL, 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.', NULL, 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.', 'Antagonism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47173/', '[1] "Product Information. Neulasta (pegfilgrastim)." Amgen, Thousand Oaks, CA.[2] "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47104, 'Brentuximab vedotin', 'Peginterferon alfa-2a', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47174/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47105, 'Brentuximab vedotin', 'Peginterferon alfa-2b', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47175/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47106, 'Brentuximab vedotin', 'Peginterferon beta-1a', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47176/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47107, 'Brentuximab vedotin', 'Pemoline', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Amphetamine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline, Modafinil', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47177/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47108, 'Brentuximab vedotin', 'Perindopril', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47178/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47109, 'Brentuximab vedotin', 'Pexidartinib', 'Major', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.', NULL, 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.', NULL, 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47179/', '[1] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47110, 'Brentuximab vedotin', 'Phenylbutazone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Acetylsalicylic acid, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47180/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47111, 'Brentuximab vedotin', 'Phenytoin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47181/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47112, 'Brentuximab vedotin', 'Pirfenidone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47182/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47113, 'Brentuximab vedotin', 'Piroxicam', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Salicylic acid, Fluocinolone acetonide, Cortisone, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47183/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47114, 'Brentuximab vedotin', 'Pitavastatin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, Alirocumab', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47184/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47115, 'Brentuximab vedotin', 'Polatuzumab vedotin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47185/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47116, 'Brentuximab vedotin', 'Poliovirus type 1 antigen (formaldehyde inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47186/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47117, 'Brentuximab vedotin', 'Pomalidomide', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Amivantamab, Ramucirumab, Rituximab, Sacituzumab govitecan, Trastuzumab deruxtecan, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47187/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47118, 'Brentuximab vedotin', 'Ponatinib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47188/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47119, 'Brentuximab vedotin', 'Posaconazole', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47189/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47120, 'Brentuximab vedotin', 'Pralatrexate', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Fluorouracil, Pemetrexed, Trifluridine, Floxuridine, Decitabine, Azacitidine, Capecitabine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47190/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47121, 'Brentuximab vedotin', 'Pralsetinib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47191/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47122, 'Brentuximab vedotin', 'Pramlintide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47192/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47123, 'Brentuximab vedotin', 'Pravastatin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47193/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47124, 'Brentuximab vedotin', 'Progesterone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Norgestrel, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47194/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47125, 'Brentuximab vedotin', 'Propylthiouracil', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Potassium perchlorate', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47195/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47126, 'Brentuximab vedotin', 'Pyrazinamide', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47196/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47127, 'Brentuximab vedotin', 'Quinapril', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47197/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47128, 'Brentuximab vedotin', 'Quinidine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47198/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47129, 'Brentuximab vedotin', 'Quinine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Risdiplam, Collagenase clostridium histolyticum, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47199/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47130, 'Brentuximab vedotin', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47200/', '[1] "Product Information. Xofigo (radium Ra 223 dichloride)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47131, 'Brentuximab vedotin', 'Ramipril', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47201/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47132, 'Brentuximab vedotin', 'Ranolazine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47202/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47133, 'Brentuximab vedotin', 'Regorafenib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47203/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47134, 'Brentuximab vedotin', 'Remdesivir', 'Moderate', 'Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.', NULL, 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.', NULL, 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47204/', '[1] Gilead Sciences, Inc "About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir." ([2020]):[2] US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download." ([2020, May 1]]):[3] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf." ([2020 Apr 03]):[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47135, 'Brentuximab vedotin', 'Repaglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47205/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47136, 'Brentuximab vedotin', 'Ribociclib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47206/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47137, 'Brentuximab vedotin', 'Rifampicin', 'Moderate', 'Coadministration with rifampin may decrease the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity such as rifampin may potentiate the risk of liver injury.', NULL, 'The potential for diminished efficacy of brentuximab vedotin and increased risk of hepatic injury should be considered when brentuximab vedotin is used with rifampin.', NULL, 'The potential for diminished efficacy of brentuximab vedotin and increased risk of hepatic injury should be considered when brentuximab vedotin is used with rifampin. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Metabolism, Synergism', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47207/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47138, 'Brentuximab vedotin', 'Rilonacept', 'Moderate', 'The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.', NULL, 'The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.', NULL, 'The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47208/', '[1] "Product Information. Kineret (anakinra)." Amgen, Thousand Oaks, CA.[2] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47139, 'Brentuximab vedotin', 'Rilpivirine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47209/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47140, 'Brentuximab vedotin', 'Riluzole', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47210/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47141, 'Brentuximab vedotin', 'Ritonavir', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47211/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47142, 'Brentuximab vedotin', 'Rofecoxib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47212/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47143, 'Brentuximab vedotin', 'Roflumilast', 'Moderate', 'The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.', NULL, 'According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.', NULL, 'According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).', 'Synergism', 'Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47213/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Daxas (roflumilast)." Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Daxas (roflumilast)." Nycomed Inc, Princeton, NJ.[5] "Product Information. Daliresp (roflumilast)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47144, 'Brentuximab vedotin', 'Rolapitant', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Nabilone, Granisetron, Scopolamine, Dronabinol, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47214/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47145, 'Brentuximab vedotin', 'Rosiglitazone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47215/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47146, 'Brentuximab vedotin', 'Rosuvastatin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Amlodipine, Valsartan, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide, Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47216/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47147, 'Brentuximab vedotin', 'Rotavirus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47217/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47148, 'Brentuximab vedotin', 'Rubella virus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47218/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47149, 'Brentuximab vedotin', 'Samarium (153Sm) lexidronam', 'Major', 'Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.', NULL, 'The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.', NULL, 'The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47219/', '[1] "Product Information. Quadramet (samarium sm 153 lexidronam)" Berlex Laboratories, Richmond, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47150, 'Brentuximab vedotin', 'Saquinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Metabolism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47220/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47151, 'Brentuximab vedotin', 'Sarecycline', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Tetracycline, Oxytetracycline, Doxycycline, Omadacycline, Eravacycline, Demeclocycline, Tigecycline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47221/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47152, 'Brentuximab vedotin', 'Sargramostim', 'Moderate', 'INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.', NULL, 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.', NULL, 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.', 'Antagonism', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47222/', '[1] "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA.[2] "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA.[3] "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA.[4] "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47153, 'Brentuximab vedotin', 'Sarilumab', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47223/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47154, 'Brentuximab vedotin', 'Pfizer-BioNTech Covid-19 Vaccine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47224/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47155, 'Brentuximab vedotin', 'Satralizumab', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47225/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47156, 'Brentuximab vedotin', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47226/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47157, 'Brentuximab vedotin', 'Secnidazole', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Furazolidone, Quinacrine, Nitazoxanide, Tetracycline, Norfloxacin, Cefepime, Ciprofloxacin, Cefuroxime, Cefixime, Amikacin, Ofloxacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47227/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47158, 'Brentuximab vedotin', 'Selpercatinib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47228/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47159, 'Brentuximab vedotin', 'Semaglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47229/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47160, 'Brentuximab vedotin', 'Simeprevir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47230/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47161, 'Brentuximab vedotin', 'Simvastatin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Guar gum, Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47231/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47162, 'Brentuximab vedotin', 'Siponimod', 'Major', 'Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.', NULL, 'The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', NULL, 'The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47232/', '[1] "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47163, 'Brentuximab vedotin', 'Sipuleucel-T', 'Moderate', 'Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.', NULL, 'Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.', NULL, 'Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.', 'Others', 'Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47233/', '[1] "Product Information. Provenge (sipuleucel-T)." Dendreon Corporation, Seattle, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47164, 'Brentuximab vedotin', 'Sitagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47234/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47165, 'Brentuximab vedotin', 'Smallpox (Vaccinia) Vaccine, Live', 'Major', 'The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47235/', '[1] "Product Information. Dryvax (smallpox vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention "Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov" ([2002 Oct 16]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47166, 'Brentuximab vedotin', 'Sodium phosphate, monobasic (p32)', 'Moderate', 'The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47236/', '[1] AnazaoHealth Corporation "P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78" ([2012 Jun]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47167, 'Brentuximab vedotin', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47237/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47168, 'Brentuximab vedotin', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47238/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47169, 'Brentuximab vedotin', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47239/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47170, 'Brentuximab vedotin', 'Sorafenib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47240/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47171, 'Brentuximab vedotin', 'Spironolactone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Eplerenone, Amiloride, Triamterene, Finerenone', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47241/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47172, 'Brentuximab vedotin', 'Stanozolol', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47242/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47173, 'Brentuximab vedotin', 'Stavudine', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47243/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47174, 'Brentuximab vedotin', 'Strontium chloride Sr-89', 'Moderate', 'The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47244/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Multum Information Services, Inc. Expert Review Panel"', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47175, 'Brentuximab vedotin', 'Sulfadiazine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Trimethoprim, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47245/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47176, 'Brentuximab vedotin', 'Sulfadoxine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Tamsulosin, Ascorbic acid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47246/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47177, 'Brentuximab vedotin', 'Sulfamethizole', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Trimethoprim, Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tamsulosin, Ascorbic acid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47247/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47178, 'Brentuximab vedotin', 'Sulfamethoxazole', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Trimethoprim, Tamsulosin, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47248/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47179, 'Brentuximab vedotin', 'Sulfasalazine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47249/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47180, 'Brentuximab vedotin', 'Sulfisoxazole', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Trimethoprim, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47250/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47181, 'Brentuximab vedotin', 'Sulindac', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47251/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47182, 'Brentuximab vedotin', 'Sunitinib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47252/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47183, 'Brentuximab vedotin', 'Tacrine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rivastigmine, Galantamine, Donepezil, Memantine, Ginkgo biloba, Aducanumab', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47253/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47184, 'Brentuximab vedotin', 'Tacrolimus', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47254/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47185, 'Brentuximab vedotin', 'Tagraxofusp', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47255/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47186, 'Brentuximab vedotin', 'Talimogene laherparepvec', 'Major', 'Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient''s immune system has sufficiently recovered.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47256/', '[1] "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA, Thousand Oaks, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47187, 'Brentuximab vedotin', 'Tamoxifen', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Relugolix, Degarelix, Aminoglutethimide, Exemestane', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47257/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47188, 'Brentuximab vedotin', 'Telaprevir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Metabolism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47258/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47189, 'Brentuximab vedotin', 'Telbivudine', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47259/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47190, 'Brentuximab vedotin', 'Telithromycin', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Dirithromycin, Lincomycin, Clindamycin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47260/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47191, 'Brentuximab vedotin', 'Telotristat ethyl', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47261/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47192, 'Brentuximab vedotin', 'Temozolomide', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Thiotepa, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Mechlorethamine, Bendamustine, Melphalan, Ifosfamide, Melphalan flufenamide, Uracil mustard', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47262/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47193, 'Brentuximab vedotin', 'Teniposide', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47263/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47194, 'Brentuximab vedotin', 'Terbinafine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Griseofulvin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47264/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47195, 'Brentuximab vedotin', 'Teriflunomide', 'Major', 'The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', NULL, 'Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa.', NULL, 'Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide''s active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47265/', '[1] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47196, 'Brentuximab vedotin', 'Testosterone (topical)', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Estradiol', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47266/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47197, 'Brentuximab vedotin', 'Thalidomide', 'Moderate', 'Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible.', NULL, 'Caution is advised if thalidomide is used in combination with other neurotoxic agents.', NULL, 'Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Trastuzumab deruxtecan, Olaratumab, Panitumumab, Tafasitamab, Obinutuzumab, Amivantamab, Ramucirumab, Belantamab mafodotin, Mogamulizumab, Blinatumomab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47267/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6[3] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47198, 'Brentuximab vedotin', 'Tioguanine', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', NULL, 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', 'Fluorouracil, Pemetrexed, Trifluridine, Floxuridine, Decitabine, Azacitidine, Capecitabine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47268/', '[1] "Product Information. Aubagio (teriflunomide)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Tabloid (thioguanine)." Prasco Laboratories, Cincinnati, OH.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47199, 'Brentuximab vedotin', 'Tinidazole', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Tetracycline, Norfloxacin, Cefepime, Ciprofloxacin, Cefuroxime, Cefixime, Amikacin, Ofloxacin, Pantoprazole, Tetracycline, Rabeprazole, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47269/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47200, 'Brentuximab vedotin', 'Tipranavir', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47270/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47201, 'Brentuximab vedotin', 'Tizanidine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Carisoprodol, Orphenadrine, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47271/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47202, 'Brentuximab vedotin', 'Tocilizumab', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47272/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47203, 'Brentuximab vedotin', 'Tofacitinib', 'Major', 'Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.', NULL, 'Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.', NULL, 'Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47273/', '[1] "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47204, 'Brentuximab vedotin', 'Tolazamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47274/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47205, 'Brentuximab vedotin', 'Tolbutamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47275/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47206, 'Brentuximab vedotin', 'Tolcapone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47276/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47207, 'Brentuximab vedotin', 'Tolmetin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47277/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47208, 'Brentuximab vedotin', 'Tolvaptan', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47278/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47209, 'Brentuximab vedotin', 'Topotecan', 'Moderate', 'The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.', NULL, 'Caution is advised if topotecan is used with other cytotoxic agents.', NULL, 'Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47279/', '[1] "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47210, 'Brentuximab vedotin', 'Trabectedin', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47280/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47211, 'Brentuximab vedotin', 'Trandolapril', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47281/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47212, 'Brentuximab vedotin', 'Tretinoin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47282/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47213, 'Brentuximab vedotin', 'Trichophyton mentagrophytes', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47283/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47214, 'Brentuximab vedotin', 'Trimetrexate', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Furazolidone, Quinacrine, Nitazoxanide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47284/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47215, 'Brentuximab vedotin', 'Troglitazone', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Guar gum', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47285/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47216, 'Brentuximab vedotin', 'Troleandomycin', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dirithromycin, Lincomycin, Clindamycin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47286/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47217, 'Brentuximab vedotin', 'Trovafloxacin', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Enoxacin, Gatifloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Ciprofloxacin, Lomefloxacin, Grepafloxacin, Cinoxacin, Delafloxacin, Sparfloxacin, Ofloxacin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47287/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47218, 'Brentuximab vedotin', 'Tuberculin purified protein derivative', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47288/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47219, 'Brentuximab vedotin', 'Tucatinib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47289/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47220, 'Brentuximab vedotin', 'Typhoid vaccine (inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47290/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47221, 'Brentuximab vedotin', 'Typhoid vaccine (live)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47291/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47222, 'Brentuximab vedotin', 'Ulipristal', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47292/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47223, 'Brentuximab vedotin', 'Upadacitinib', 'Major', 'Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.', NULL, 'Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.', NULL, 'Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47293/', '[1] "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47224, 'Brentuximab vedotin', 'Ustekinumab', 'Moderate', 'The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', NULL, 'Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.', 'Others', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47294/', '[1] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47225, 'Brentuximab vedotin', 'Valdecoxib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47295/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47226, 'Brentuximab vedotin', 'Valganciclovir', 'Moderate', 'The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.', NULL, 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.', NULL, 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47296/', '[1] "Product Information. Valcyte (valganciclovir)" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA.[5] "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A "Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects." J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J "Effect of food on the relative bioavailability of oral ganciclovir." J Clin Pharmacol 36 (1996): 238-41', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47227, 'Brentuximab vedotin', 'Vandetanib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Ripretinib, Ruxolitinib, Dasatinib, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47297/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47228, 'Brentuximab vedotin', 'Varicella Zoster Vaccine (Recombinant)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47298/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47229, 'Brentuximab vedotin', 'Vemurafenib', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Probenecid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47299/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47230, 'Brentuximab vedotin', 'Verapamil', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Absorption', 'Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47300/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47231, 'Brentuximab vedotin', 'Vinblastine', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47301/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47232, 'Brentuximab vedotin', 'Vincristine', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47302/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47233, 'Brentuximab vedotin', 'Vincristine (liposome)', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47303/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47234, 'Brentuximab vedotin', 'Vinorelbine', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Irinotecan', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47304/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[2] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics, New York, NY.[3] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[5] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[6] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47235, 'Brentuximab vedotin', 'Voriconazole', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47305/', '[1] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47236, 'Brentuximab vedotin', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47306/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47237, 'Brentuximab vedotin', 'Zafirlukast', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47307/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47238, 'Brentuximab vedotin', 'Zalcitabine', 'Moderate', 'Zalcitabine can cause peripheral neuropathy in up to one-third of patients with advanced HIV disease, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Zalcitabine-related peripheral neuropathy is a sensorimotor neuropathy characterized initially by numbness and burning dysesthesia involving the distal extremities. These symptoms may be followed by sharp shooting pains or severe continuous burning pain if the drug is not withdrawn, and progress to severe pain requiring narcotic analgesics. The neuropathy is potentially irreversible. However, with prompt discontinuation of zalcitabine, it is usually slowly reversible, although symptoms may initially progress following discontinuation.', NULL, 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible.', NULL, 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible. Otherwise, careful monitoring is recommended for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness in the extremities, particularly in patients with a low CD4 cell count or diabetes. Since the development of peripheral neuropathy appears to be dose-related, the recommended dosage of zalcitabine should not be exceeded. Patients should be advised to promptly discontinue zalcitabine therapy and contact their physician if neuropathy develops. Therapy may be reinstituted following resolution of neuropathy symptoms, but dosage should be reduced to one-half the initially recommended dosage. Zalcitabine should be permanently discontinued in patients who develop severe peripheral neuropathy during treatment.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47308/', '[1] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.[3] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47239, 'Brentuximab vedotin', 'Zidovudine', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More', 'Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47309/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47240, 'Brentuximab vedotin', 'Zileuton', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47310/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47241, 'Brexanolone', 'Oxitriptan', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47311/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47242, 'Amoxapine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47312/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47243, 'Brexanolone', 'Azatadine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47313/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47244, 'Brexanolone', 'Belladonna', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47314/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47245, 'Brexpiprazole', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47315/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47246, 'Brimonidine (ophthalmic)', 'Brexanolone', 'Moderate', 'Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.', 'Synergism', 'Tacrolimus, Minoxidil, Deoxycholic acid, Magnesium sulfate, Glycopyrronium, Calcium gluconate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47316/', '[1] "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc, Cranbury, NJ.[2] "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[5] Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47247, 'Brimonidine (topical)', 'Brexanolone', 'Moderate', 'Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.', 'Synergism', 'Tacrolimus, Minoxidil, Deoxycholic acid, Magnesium sulfate, Glycopyrronium, Calcium gluconate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47317/', '[1] "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc, Cranbury, NJ.[2] "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[5] Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47248, 'Brivaracetam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47318/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47249, 'Bromocriptine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine, Ritodrine, Bremelanotide, Black cohosh, Naproxen, Ibuprofen', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47319/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47250, 'Brompheniramine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47320/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47251, 'Buprenorphine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47321/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47252, 'Buspirone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47322/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47253, 'Butabarbital', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47323/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47254, 'Butalbital', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47324/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47255, 'Butorphanol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47325/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47256, 'Cabergoline', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine, Ritodrine, Bremelanotide, Black cohosh, Naproxen, Ibuprofen', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47326/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47257, 'Cannabidiol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47327/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47258, 'Carbamazepine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47328/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47259, 'Brexanolone', 'Pentoxyverine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Benzonatate, Dextromethorphan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47329/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47260, 'Carbinoxamine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47330/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47261, 'Cariprazine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47331/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47262, 'Carisoprodol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47332/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47263, 'Cenobamate', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47333/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47264, 'Clofedanol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Benzonatate, Dextromethorphan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47334/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47265, 'Chloral hydrate', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47335/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47266, 'Chlorcyclizine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47336/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47267, 'Chlordiazepoxide', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47337/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47268, 'Chlormezanone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47338/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47269, 'Chlorphenesin', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47339/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47270, 'Chlorpromazine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47340/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47271, 'Chlorzoxazone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47341/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47272, 'Citalopram', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47342/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47273, 'Clemastine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47343/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47274, 'Clobazam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47344/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47275, 'Clomipramine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47345/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47276, 'Clonazepam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47346/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47277, 'Clonidine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47347/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47278, 'Clorazepic acid', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47348/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47279, 'Clozapine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47349/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47280, 'Cyclizine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47350/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47281, 'Cyclobenzaprine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47351/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47282, 'Cyproheptadine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47352/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47283, 'Dantrolene', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47353/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47284, 'Desipramine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47354/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47285, 'Desvenlafaxine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47355/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47286, 'Deutetrabenazine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Dextromethorphan, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47356/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47287, 'Dexbrompheniramine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47357/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47288, 'Dexmedetomidine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47358/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47289, 'Dezocine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47359/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47290, 'Diazepam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47360/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47291, 'Dicyclomine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Mepenzolate, Alosetron, Glycopyrronium, Papaverine, Propantheline, Isometheptene', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47361/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47292, 'Dimenhydrinate', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47362/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47293, 'Diphenhydramine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47363/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47294, 'Brexanolone', 'Valproic acid', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47364/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47295, 'Doxazosin', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Guanethidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47365/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47296, 'Doxepin', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine, Lidocaine, Tetracaine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47366/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47297, 'Doxepin (topical)', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine, Lidocaine, Tetracaine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47367/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47298, 'Doxylamine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47368/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47299, 'Dronabinol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47369/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47300, 'Droperidol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47370/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47301, 'Duloxetine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47371/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47302, 'Entacapone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47372/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47303, 'Escitalopram', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47373/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47304, 'Esketamine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine, Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47374/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47305, 'Eslicarbazepine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47375/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47306, 'Estazolam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47376/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47307, 'Eszopiclone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47377/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47308, 'Ethchlorvynol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47378/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47309, 'Ethosuximide', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47379/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47310, 'Ethotoin', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47380/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47311, 'Ezogabine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47381/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47312, 'Felbamate', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47382/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47313, 'Flavoxate', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47383/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47314, 'Flibanserin', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ritodrine, Bremelanotide, Black cohosh, Naproxen, Ibuprofen', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47384/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47315, 'Fluoxetine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47385/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47316, 'Fluphenazine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47386/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47317, 'Flurazepam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47387/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47318, 'Guanabenz', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47388/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47319, 'Guanfacine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Rauwolfia serpentina root, Reserpine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47389/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47320, 'Halazepam', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47390/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47321, 'Haloperidol', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47391/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47322, 'Diamorphine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47392/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47323, 'Hydrocodone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Benzonatate, Dextromethorphan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47393/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47324, 'Hydromorphone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47394/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47325, 'Hydroxyzine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47395/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47326, 'Ifosfamide', 'Brexanolone', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47396/', '[1] Simonian NA, Gilliam FG, Chiappa KH "Ifosfamide causes a diazepam-sensitive encephalopathy." Neurology 43 (1993): 2700-2[2] "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47327, 'Iloperidone', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47397/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47328, 'Imipramine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47398/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47329, 'Isocarboxazid', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47399/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47330, 'Brexanolone', 'Kava', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47400/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47331, 'Brexanolone', 'Lacosamide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47401/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47332, 'Brexanolone', 'Lamotrigine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47402/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47333, 'Brexanolone', 'Lasmiditan', 'Moderate', 'Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions. Patients treated with lasmiditan are at risk of CNS depression, including dizziness and sedation, as well as driving impairment.', NULL, 'Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.', NULL, 'Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation. Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.', 'Synergism', 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47403/', '[1] "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47334, 'Brexanolone', 'Lemborexant', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47404/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47335, 'Brexanolone', 'Levetiracetam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47405/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47336, 'Brexanolone', 'Levocetirizine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47406/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47337, 'Brexanolone', 'Levodopa', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47407/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47338, 'Brexanolone', 'Levacetylmethadol', 'Major', 'The central nervous system and respiratory depressant effects of levomethadyl acetate may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.', NULL, 'Caution and dosage adjustments are advisable if CNS depressants are prescribed to patients on levomethadyl acetate maintenance.', NULL, 'Caution and dosage adjustments are advisable if CNS depressants are prescribed to patients on levomethadyl acetate maintenance. Alcohol use should be avoided, and patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them. Patients who are known to abuse sedatives, tranquilizers, antidepressants, benzodiazepines, and alcohol should be warned of the risk of serious and potentially fatal overdose if these substances are taken concurrently.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47408/', '[1] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[2] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[3] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47339, 'Brexanolone', 'Levomilnacipran', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47409/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47340, 'Brexanolone', 'Levorphanol', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47410/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47341, 'Brexanolone', 'Lithium carbonate', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47411/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47342, 'Brexanolone', 'Lofexidine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47412/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47343, 'Brexanolone', 'Lorazepam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47413/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47344, 'Brexanolone', 'Loxapine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47414/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47345, 'Brexanolone', 'Lumateperone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47415/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47346, 'Brexanolone', 'Lurasidone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47416/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47347, 'Brexanolone', 'Maprotiline', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47417/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47348, 'Brexanolone', 'Meclizine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47418/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47349, 'Brexanolone', 'Melatonin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47419/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47350, 'Brexanolone', 'Meperidine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47420/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47351, 'Brexanolone', 'Mephenytoin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47421/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47352, 'Brexanolone', 'Methylphenobarbital', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine, Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47422/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47353, 'Brexanolone', 'Meprobamate', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47423/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47354, 'Brexanolone', 'Mesoridazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47424/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47355, 'Brexanolone', 'Metaxalone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47425/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47356, 'Brexanolone', 'Methadone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47426/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47357, 'Brexanolone', 'Methdilazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47427/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47358, 'Brexanolone', 'Methocarbamol', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47428/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47359, 'Brexanolone', 'Methotrimeprazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47429/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47360, 'Brexanolone', 'Methsuximide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47430/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47361, 'Brexanolone', 'Methyldopa', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Rauwolfia serpentina root, Reserpine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47431/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47362, 'Brexanolone', 'Metoclopramide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Cisapride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47432/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47363, 'Brexanolone', 'Metyrosine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47433/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47364, 'Brexanolone', 'Midazolam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47434/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47365, 'Brexanolone', 'Milnacipran', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47435/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47366, 'Brexanolone', 'Mirtazapine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47436/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47367, 'Brexanolone', 'Molindone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47437/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47368, 'Brexanolone', 'Morphine (liposomal)', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47438/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47369, 'Brexanolone', 'Nabilone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47439/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47370, 'Brexanolone', 'Nalbuphine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47440/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47371, 'Brexanolone', 'Nefazodone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47441/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47372, 'Brexanolone', 'Nortriptyline', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47442/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47373, 'Brexanolone', 'Olanzapine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47443/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47374, 'Brexanolone', 'Oliceridine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47444/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47375, 'Brexanolone', 'Olopatadine (nasal)', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47445/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47376, 'Brexanolone', 'Opicapone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47446/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47377, 'Brexanolone', 'Opium', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47447/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47378, 'Brexanolone', 'Orphenadrine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47448/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47379, 'Brexanolone', 'Oxazepam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47449/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47380, 'Brexanolone', 'Oxcarbazepine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47450/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47381, 'Brexanolone', 'Oxycodone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47451/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47382, 'Brexanolone', 'Oxymorphone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47452/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47383, 'Brexanolone', 'Paliperidone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47453/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47384, 'Brexanolone', 'Paraldehyde', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47454/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47385, 'Brexanolone', 'Paramethadione', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47455/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47386, 'Brexanolone', 'Paroxetine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47456/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47387, 'Brexanolone', 'Pentazocine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47457/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47388, 'Brexanolone', 'Pentobarbital', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47458/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47389, 'Brexanolone', 'Perampanel', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47459/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47390, 'Brexanolone', 'Pergolide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47460/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47391, 'Brexanolone', 'Perphenazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47461/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47392, 'Brexanolone', 'Phenacemide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47462/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47393, 'Brexanolone', 'Phenelzine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47463/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47394, 'Brexanolone', 'Phenindamine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47464/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47395, 'Brexanolone', 'Phenobarbital', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital, Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47465/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47396, 'Brexanolone', 'Phensuximide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47466/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47397, 'Brexanolone', 'Phenytoin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47467/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47398, 'Brexanolone', 'Pimavanserin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47468/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47399, 'Brexanolone', 'Pimozide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47469/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47400, 'Brexanolone', 'Pramipexole', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47470/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47401, 'Brexanolone', 'Prazosin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Rauwolfia serpentina root, Hydralazine, Reserpine, Guanethidine, Deserpidine, Guanethidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47471/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47402, 'Brexanolone', 'Pregabalin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47472/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47403, 'Brexanolone', 'Primidone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital, Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47473/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47404, 'Brexanolone', 'Procarbazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47474/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47405, 'Brexanolone', 'Prochlorperazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47475/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47406, 'Brexanolone', 'Procyclidine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47476/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47407, 'Brexanolone', 'Promazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47477/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47408, 'Brexanolone', 'Promethazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine, Hydroxocobalamin, Fomepizole, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47478/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47409, 'Brexanolone', 'Propiomazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47479/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47410, 'Dextropropoxyphene', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47480/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47411, 'Brexanolone', 'Protriptyline', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47481/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47412, 'Brexanolone', 'Mepyramine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Lidocaine, Tetracaine, Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47482/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47413, 'Brexanolone', 'Quazepam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47483/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47414, 'Brexanolone', 'Quetiapine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47484/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47415, 'Brexanolone', 'Ramelteon', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47485/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47416, 'Brexanolone', 'Rasagiline', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47486/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47417, 'Brexanolone', 'Remifentanil', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47487/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47418, 'Brexanolone', 'Remimazolam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47488/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47419, 'Brexanolone', 'Risperidone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47489/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47420, 'Brexanolone', 'Ropinirole', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47490/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47421, 'Brexanolone', 'Rotigotine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47491/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47422, 'Brexanolone', 'Rufinamide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47492/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47423, 'Brexanolone', 'Safinamide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47493/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47424, 'Brexanolone', 'Scopolamine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital, Ketorolac, Homatropine, Methscopolamine, Ephedrine, Tropicamide, Phenylephrine, Granisetron, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47494/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47425, 'Brexanolone', 'Secobarbital', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47495/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47426, 'Brexanolone', 'Selegiline', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47496/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47427, 'Brexanolone', 'Sertraline', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47497/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47428, 'Brexanolone', 'Sodium oxybate', 'Major', 'The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.', NULL, 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.', NULL, 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.', 'Synergism', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47498/', '[1] "Product Information. Xyrem (sodium oxybate)." Orphan Medical, Minnetonka, MN.[2] "Product Information. Xywav (calcium/magnesium/potass/sodium oxybates)." Jazz Pharmaceuticals, Palo Alto, CA.[3] "Product Information. Xyrem (sodium oxybate)." Orphan Medical, Minnetonka, MN.[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47429, 'Brexanolone', 'St. John''s Wort', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47499/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47430, 'Brexanolone', 'Stiripentol', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47500/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47431, 'Brexanolone', 'Sufentanil', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47501/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47432, 'Brexanolone', 'Suvorexant', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47502/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47433, 'Brexanolone', 'Tapentadol', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47503/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47434, 'Brexanolone', 'Tasimelteon', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47504/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47435, 'Brexanolone', 'Temazepam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47505/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47436, 'Brexanolone', 'Terazosin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Tamsulosin, Alfuzosin, Tadalafil, Finasteride, Silodosin, Dutasteride, Solifenacin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47506/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47437, 'Brexanolone', 'Tetrabenazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Dextromethorphan, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47507/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47438, 'Brexanolone', 'Thalidomide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47508/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47439, 'Brexanolone', 'Thiethylperazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47509/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47440, 'Brexanolone', 'Thioridazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47510/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47441, 'Brexanolone', 'Thiothixene', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47511/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47442, 'Brexanolone', 'Tiagabine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47512/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47443, 'Brexanolone', 'Tizanidine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47513/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47444, 'Brexanolone', 'Tolcapone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47514/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47445, 'Brexanolone', 'Topiramate', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47515/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47446, 'Brexanolone', 'Tranylcypromine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47516/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47447, 'Brexanolone', 'Trazodone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47517/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47448, 'Brexanolone', 'Triazolam', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47518/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47449, 'Brexanolone', 'Trifluoperazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47519/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47450, 'Brexanolone', 'Triflupromazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47520/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47451, 'Brexanolone', 'Trihexyphenidyl', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47521/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47452, 'Alimemazine', 'Brexanolone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47522/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47453, 'Brexanolone', 'Trimethadione', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47523/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47454, 'Brexanolone', 'Trimethobenzamide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47524/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47455, 'Brexanolone', 'Trimipramine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47525/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47456, 'Brexanolone', 'Tripelennamine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47526/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47457, 'Brexanolone', 'Triprolidine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47527/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47458, 'Brexanolone', 'Tryptophan', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47528/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47459, 'Brexanolone', 'Valbenazine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Dextromethorphan, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47529/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47460, 'Brexanolone', 'Valerian', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47530/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47461, 'Brexanolone', 'Venlafaxine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47531/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47462, 'Brexanolone', 'Vigabatrin', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47532/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47463, 'Brexanolone', 'Vilazodone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47533/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47464, 'Brexanolone', 'Vortioxetine', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Viloxazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47534/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47465, 'Brexanolone', 'Zaleplon', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47535/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47466, 'Brexanolone', 'Ziconotide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47536/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47467, 'Brexanolone', 'Ziprasidone', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Amisulpride', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47537/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47468, 'Brexanolone', 'Zolpidem', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Nitrazepam, Zopiclone, Thiopental, Methohexital', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47538/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47469, 'Brexanolone', 'Zonisamide', 'Moderate', 'Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.', NULL, 'Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.', 'Synergism', 'Fenfluramine, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47539/', '[1] "Product Information. Zulresso (brexanolone)." Sage Therapeutics, Inc., Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47470, 'Brexpiprazole', 'Acetohexamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Chlorpropamide, Guar gum, Rosuvastatin', 'Methotrimeprazine, Promazine, Haloperidol, Thiothixene, Pimavanserin, Pimozide, Amisulpride, Triflupromazine, Loxapine, Molindone, Droperidol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47540/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47471, 'Amoxapine', 'Brexpiprazole', 'Moderate', 'Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.', 'Synergism', 'Oxitriptan, Vilazodone, Vortioxetine, Tryptophan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47541/', '[1] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP "Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated." Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM "Interaction between some anticholinergic agents and phenothiazines." Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R "Heat stroke in phenothiazine-treated patients: a report of three fatalities." Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952]." Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry 31 (1986): 339-41[10] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983): 957-9[13] "Product Information. Cogentin (benztropine)." Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7[15] Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47472, 'Amprenavir', 'Brexpiprazole', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.', 'Metabolism', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47542/', '[1] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47473, 'Amyl Nitrite', 'Brexpiprazole', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47543/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47474, 'Brexpiprazole', 'Azatadine', 'Moderate', 'Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Methotrimeprazine, Promazine, Pimavanserin, Amisulpride, Triflupromazine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47544/', '[1] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP "Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated." Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM "Interaction between some anticholinergic agents and phenothiazines." Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R "Heat stroke in phenothiazine-treated patients: a report of three fatalities." Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952]." Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry 31 (1986): 339-41[10] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983): 957-9[13] "Product Information. Cogentin (benztropine)." Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7[15] Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47475, 'Brexpiprazole', 'Belladonna', 'Moderate', 'Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47545/', '[1] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP "Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated." Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM "Interaction between some anticholinergic agents and phenothiazines." Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R "Heat stroke in phenothiazine-treated patients: a report of three fatalities." Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952]." Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry 31 (1986): 339-41[10] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983): 957-9[13] "Product Information. Cogentin (benztropine)." Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7[15] Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47476, 'Brexpiprazole', 'Bendroflumethiazide', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 'Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47546/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47477, 'Brexpiprazole', 'Benzthiazide', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 'Methotrimeprazine, Triflupromazine, Promazine, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47547/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47478, 'Brexpiprazole', 'Bepridil', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Methotrimeprazine, Triflupromazine, Promazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47548/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47479, 'Brexpiprazole', 'Berotralstat', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.', 'Metabolism', 'Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, Molindone, Paliperidone', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47549/', '[1] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47480, 'Brexpiprazole', 'Boceprevir', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.', 'Metabolism', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47550/', '[1] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47481, 'Brigatinib', 'Brexpiprazole', 'Moderate', 'Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.', NULL, 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever brigatinib is added to or withdrawn from therapy.', 'Metabolism', 'Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Lurasidone, More', 'Entrectinib, Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47551/', '[1] "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47482, 'Brimonidine (ophthalmic)', 'Brexpiprazole', 'Moderate', 'Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.', 'Synergism', 'Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, Abrocitinib, More', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47552/', '[1] "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc, Cranbury, NJ.[2] "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[5] Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47483, 'Brimonidine (topical)', 'Brexpiprazole', 'Moderate', 'Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness.', NULL, 'Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.', 'Synergism', 'Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, Abrocitinib, More', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47553/', '[1] "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc, Cranbury, NJ.[2] "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc, Irvine, CA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[5] Pekdemir M, Yanturali S, Karakus G "More than just an ocular solution." Emerg Med J 22 (2005): 753-4[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47484, 'Brivaracetam', 'Brexpiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Lacosamide', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47554/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47485, 'Bromocriptine', 'Brexpiprazole', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', NULL, 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', NULL, 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Ritodrine, Bremelanotide, Black cohosh, Naproxen, Ibuprofen', 'Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47555/', '[1] Weingarten JC, Thompson TL "The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report." Gen Hosp Psychiatry 7 (1985): 364-6[2] "Product Information. Norprolac (quinagolide)." Ferring Inc, North York, IA.[3] "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.[4] "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[8] "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.[9] "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.[10] Robbins RJ, Kern PA, Thompson TL "Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma." Am J Med 76 (1984): 921-3[11] Yahr MD, Duvoisin RC "Drug therapy of parkinsonism." N Engl J Med 287 (1972): 20-4[12] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[13] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9[14] "Product Information. Permax (pergolide)." Athena Neurosciences Inc, South San Francisco, CA.[15] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[16] "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[20] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47486, 'Brompheniramine', 'Brexpiprazole', 'Moderate', 'Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47556/', '[1] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP "Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated." Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM "Interaction between some anticholinergic agents and phenothiazines." Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R "Heat stroke in phenothiazine-treated patients: a report of three fatalities." Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952]." Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry 31 (1986): 339-41[10] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983): 957-9[13] "Product Information. Cogentin (benztropine)." Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7[15] Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47487, 'Bumetanide', 'Brexpiprazole', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 'Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47557/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47488, 'Buprenorphine', 'Brexpiprazole', 'Major', 'Concomitant use of buprenorphine with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may increase the risk of buprenorphine overdose, severe respiratory depression, coma, and death.', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them. Extreme caution is advised when prescribing buprenorphine to patients who are addicted to opioids and also abusing benzodiazepines or alcohol. Due to potential risk of overdose and death, dependence on sedative-hypnotics such as benzodiazepines or alcohol is considered a relative contraindication for office-based buprenorphine treatment of opioid addiction.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47558/', '[1] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8[2] Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I "A critical review of the causes of death among post-morten toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths." Addiction 99 (2004): 978-88[3] Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ "Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes." Drug Alcohol Depend 132 (2013): 580-6[4] Tracqui A, Kintz P, Ludes B "Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities." J Anal Toxicol 22 (1998): 430-4[5] Kintz P "A new series of 13 buprenorphine-related deaths." Clin Biochem 35 (2002): 513-6[6] Kilicarslan T, Sellers EM "Lack of interaction of buprenorphine with flunitrazepam metabolism." Am J Psychiatry 157 (2000): 1164-6[7] Martin HA "The possible consequences of combining lorazepam and buprenorphine/naloxone: a case review." J Emerg Nurs 37 (2011): 200-2[8] Reynaud M, Tracqui A, Petit G, Potard D, Courty P "Six deaths linked to misuse of buprenorphine-benzodiazepine combinations." Am J Psychiatry 155 (1998): 448-9[9] "Product Information. Suboxone (buprenorphine-naloxone)." Reckitt and Colman Pharmaceuticals Inc, Richmond, VA.[10] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):[11] Hakkinen M, Launiainen T, Vuori E, Ojanpera I "Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning." Eur J Clin Pharmacol 68 (2012): 301-9[12] Substance Abuse and Mental Health Services Administration (US) "Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series, No. 40 Available from: URL: http://www.ncbi.nlm.nih.gov/books/NBK64245/" ([2004]):[13] Ferrant O, Papin F, Clin B, et al "Fatal poisoning due to snorting buprenorphine and alcohol consumption." Forensic Sci Int 204 (2011): e8-11[14] Kintz P "Deaths involving buprenorphine: a compendium of French cases." Forensic Sci Int 121 (2001): 65-9[15] Reynaud M, Petit G, Potard D, Courty P "Six deaths linked to concomitant use of buprenorphine and benzodiazepines." Addiction 93 (1998): 1385-92[16] Gueye PN, Borron SW, Risede P, et al "Buprenorphine and midazolalm act in combination to depress respiration in rats." Toxicol Sci 65 (2002): 107-14[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[20] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47489, 'Buspirone', 'Brexpiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Amisulpride, Pimavanserin, Methotrimeprazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47559/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47490, 'Butabarbital', 'Brexpiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Nitrazepam, Zopiclone', 'Amisulpride', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47560/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47491, 'Butalbital', 'Brexpiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Nitrazepam, Zopiclone', 'Amisulpride', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47561/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47492, 'Butorphanol', 'Brexpiprazole', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', NULL, 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone', 'Amisulpride', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47562/', '[1] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf." ([2016, Aug 31]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47493, 'Cabergoline', 'Brexpiprazole', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', NULL, 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', NULL, 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Ritodrine, Bremelanotide, Black cohosh, Naproxen, Ibuprofen', 'Cariprazine, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47563/', '[1] Weingarten JC, Thompson TL "The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report." Gen Hosp Psychiatry 7 (1985): 364-6[2] "Product Information. Norprolac (quinagolide)." Ferring Inc, North York, IA.[3] "Product Information. Requip (ropinirole)." SmithKline Beecham, Philadelphia, PA.[4] "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[8] "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.[9] "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.[10] Robbins RJ, Kern PA, Thompson TL "Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma." Am J Med 76 (1984): 921-3[11] Yahr MD, Duvoisin RC "Drug therapy of parkinsonism." N Engl J Med 287 (1972): 20-4[12] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[13] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9[14] "Product Information. Permax (pergolide)." Athena Neurosciences Inc, South San Francisco, CA.[15] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[16] "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[20] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47494, 'Canagliflozin', 'Brexpiprazole', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Chlorpropamide, Guar gum, Rosuvastatin', 'Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47564/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47495, 'Cannabidiol', 'Brexpiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Lacosamide', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47565/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47496, 'Captopril', 'Brexpiprazole', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47566/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47497, 'Carbamoylcholine (ophthalmic)', 'Brexpiprazole', 'Moderate', 'Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.', NULL, 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', NULL, 'Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.', 'Antagonism', 'Asenapine, Pimavanserin, Iloperidone, Amisulpride, Droperidol, Cariprazine, Paliperidone, Lurasidone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47567/', '[1] "Product Information. Pilopine HS (pilocarpine ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.[2] "Multum Information Services, Inc. Expert Review Panel"', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47498, 'Carbamazepine', 'Brexpiprazole', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of brexpiprazole, which is partially metabolized by this isoenzyme. According to product labeling, administration of brexpiprazole with a potent 3A4 inducer (rifampin) resulted in an approximately 75% decrease in AUC.', NULL, 'During concomitant use with a potent 3A4 inducer, the usual dose of brexpiprazole should be doubled over one to two weeks.', NULL, 'During concomitant use with a potent 3A4 inducer, the usual dose of brexpiprazole should be doubled over one to two weeks. When the inducer is discontinued, the brexpiprazole dose should be decreased to its original level over one to two weeks. It is advisable to monitor patients for clinical response.', 'Metabolism', 'Lacosamide', 'Amisulpride', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47568/', '[1] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[4] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47499, 'Brexpiprazole', 'Pentoxyverine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Amisulpride, Pimavanserin', 'Benzonatate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47569/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982): 791-7[10] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990): 477-82[13] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] "Product Information. Iopidine (apraclonidine)." Alcon Laboratories Inc, Fort Worth, TX.[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977): 22[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988): 63-6[23] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[24] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[25] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970): 336-8[28] "Product Information. Precedex (dexmedetomidine)" Abbott Pharmaceutical, Abbott Park, IL.[29] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981): 705-10[32] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[33] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[38] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[40] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[42] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[44] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (47500, 'Carbinoxamine', 'Brexpiprazole', 'Moderate', 'Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.', NULL, 'Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/47570/', '[1] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82[2] Mann SC, Boger WP "Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated." Am J Psychiatry 135 (1978): 1097-100[3] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3[4] Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973): 348-50[5] Gershon S, Neubauer H, Sundland DM "Interaction between some anticholinergic agents and phenothiazines." Clin Pharmacol Ther 6 (1965): 749-56[6] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571[7] Zelman S, Guillan R "Heat stroke in phenothiazine-treated patients: a report of three fatalities." Am J Psychiatry 126 (1970): 1787-90[8] Cohen MA, Alfonso CA, Mosquera M "Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952]." Am J Psychiatry 151 (1994): 619-20[9] Moreau A, Jones BD, Banno V "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry 31 (1986): 339-41[10] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8[12] Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983): 957-9[13] "Product Information. Cogentin (benztropine)." Merck & Co, Inc, West Point, PA.[14] Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7[15] Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978): 243-4[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
